What is economic evidence in the context of pharmaceutical development?

Economic evidence encompasses data demonstrating a therapy's value relative to its cost—including cost-effectiveness analyses, budget impact assessments, comparative effectiveness against existing alternatives, and real-world outcomes—used by payers and HTA bodies to justify reimbursement at a given price.

When should companies start developing economic evidence?

Economic evidence planning should ideally begin during Phase II development. This early integration allows companies to design clinical trials that capture endpoints relevant to both regulatory approval and payer requirements, avoiding costly gaps in evidence that could delay or prevent market access.

What is the difference between regulatory approval and HTA?

Regulatory approval focuses on demonstrating safety and efficacy, while HTA evaluates whether a therapy provides good value for money. HTA bodies assess cost-effectiveness, budget impact, and comparative effectiveness against existing treatments. A drug can receive regulatory approval but still face HTA rejection if it doesn't demonstrate sufficient value to justify its cost.

What are common mistakes in balancing clinical and economic evidence?

Common mistakes include starting economic planning too late, failing to align clinical endpoints with payer priorities, underestimating the importance of comparator selection, neglecting real-world evidence generation, and not engaging with payers early enough to understand their specific requirements.

How can Loon Waters™ help balance clinical and economic evidence?

Loon Waters™—our AI platform for market access and value demonstration—helps teams rapidly generate, validate, and articulate economic evidence alongside clinical data. It supports early payer landscaping, cost-effectiveness and budget-impact modelling, and real-world evidence synthesis to strengthen HTA preparedness and de-risk reimbursement.

What makes a strong cost-effectiveness model?

Strong models incorporate robust clinical data, appropriate time horizons, relevant comparators, comprehensive sensitivity analyses, and real-world inputs. They should be transparent, validated against external data, and flexible enough to adapt to different healthcare systems and payer perspectives.

When and how should companies engage with payers?

Payer engagement should begin during Phase II development through scientific advice meetings, advisory boards, and early dialogues. These interactions help companies understand evidence requirements, test value propositions, and identify potential access challenges before they become critical barriers.

What role does real-world evidence play in demonstrating value?

Real-world evidence bridges the gap between controlled trial settings and actual clinical practice. It demonstrates long-term effectiveness, safety in diverse populations, and actual healthcare resource utilization. RWE is increasingly important for supporting value propositions and managing access agreements.

Why is budget impact analysis crucial for market access?

Budget impact analysis shows payers the financial implications of adopting a new therapy within their specific healthcare system. Even cost-effective therapies can face access restrictions if the budget impact is too high. Comprehensive budget impact models help identify patient populations and usage scenarios that optimize both access and affordability.

What future trends will impact evidence requirements?

Key trends include increasing demand for real-world evidence, growth of value-based contracts, integration of digital health data, emphasis on patient-reported outcomes, and use of AI for evidence generation. Companies must build flexible evidence strategies that can adapt to these evolving requirements.

Hidden Risks in Biopharma: Clinical and Economic Evidence

The New Reality of Drug Development

In the world of biopharmaceutical development, clinical success does not automatically translate into payer acceptance or commercialization success. Companies invest billions in bringing innovative therapies to market, yet many face unexpected barriers when seeking reimbursement and market access. The disconnect between clinical excellence and economic viability represents one of the industry's most significant hidden risks.

The Dual Mandate: Clinical and Economic Evidence

This critical gap emerges from a fundamental misalignment: while regulatory bodies focus primarily on safety and efficacy, payers and health technology assessment (HTA) organizations demand comprehensive evidence of cost-effectiveness and value. Understanding and addressing this dual mandate has become essential for successful drug development and commercialization. Regulatory agencies like the FDA and EMA focus on establishing that a drug is safe and effective for its intended use.

Their evaluation criteria center on clinical trial data demonstrating therapeutic benefit and acceptable safety profiles. However, gaining regulatory approval is only the first hurdle in bringing a therapy to patients. Payers and HTA bodies operate under different mandates. They must evaluate whether a new therapy provides sufficient value relative to its cost, considering budget constraints and existing treatment alternatives.

This requires demonstrating not just that a drug works, but that it offers meaningful improvements in outcomes that justify its price point. Health Technology Assessment has become the gatekeeper for market access in many countries. HTA bodies evaluate the clinical effectiveness, cost-effectiveness, and broader societal impact of new therapies. Their recommendations directly influence reimbursement decisions and can determine whether patients gain access to innovative treatments.

Learning from Real-World Examples

Companies that fail to develop robust economic evidence alongside their clinical programs face severe consequences. These can include reimbursement delays or denials, restricted patient access, lower pricing than anticipated, and ultimately, commercial failure despite clinical success. The financial impact can be devastating, with billions in development costs failing to generate expected returns. Successful companies begin market access planning early in development, conducting comprehensive landscaping to understand payer priorities across target markets.

Strategies for Success

This includes analyzing recent HTA decisions, identifying value drivers, and anticipating future evidence requirements. Early forecasting helps align clinical development with payer expectations. Robust health economic modeling should begin during Phase II development. Early models help identify key value drivers, inform clinical trial design decisions, and guide evidence generation priorities. These models evolve throughout development, incorporating new clinical data and payer feedback to strengthen the value proposition.

Proactive engagement with payers and HTA bodies through scientific advice meetings and early dialogues provides invaluable insights. These interactions help companies understand evidence expectations, refine value propositions, and identify potential access challenges before they become insurmountable barriers. Breaking down silos between clinical development, regulatory affairs, and market access teams is essential. Successful companies establish integrated evidence planning teams that ensure clinical trials generate data supporting both regulatory approval and payer requirements.

Leveraging Technology for Evidence Excellence

This collaborative approach prevents costly misalignments and accelerates time to market. The hidden risks in biopharma development are real and costly, but they are not insurmountable. Success requires recognizing that clinical and economic evidence are two sides of the same coin — both essential for bringing innovative therapies to patients. Companies that embrace this dual mandate from the earliest stages of development position themselves for both regulatory and commercial success.

Building a Balanced Evidence Strategy

The path forward demands a fundamental shift in how we approach drug development. It requires breaking down organizational silos, embracing new technologies, and viewing payers as partners rather than obstacles. Most importantly, it requires recognizing that demonstrating value is not just about meeting regulatory requirements — it's about ensuring that breakthrough therapies reach the patients who need them. Why clinical success doesn't guarantee market access: The critical importance of balancing clinical and economic evidence in drug development "Clinical success without economic evidence is like building a bridge halfway across a river — impressive engineering, but it doesn't get you to the other side." — Dr.

Ghayath Janoudi, CEO, Loon "AI doesn't replace human expertise in evidence generation — it amplifies it, enabling teams to focus on strategic insights rather than manual data processing." — Dr. Ghayath Janoudi, CEO, Loon The companies that thrive in tomorrow's healthcare landscape will be those that master the art and science of balanced evidence generation today. The time to act is now. In this new high-stakes reimbursement environment with value-based expectations, the ability to rapidly generate, validate, iterate, and articulate compelling value evidence will enhance biopharma leaders' ability to increase competitiveness.

Discover how Loon Waters™ — our AI intelligence, forecasting, and optimization platform for Market Access and value demonstration can help enhance your HTA prepapredness and protect your assets to de-risk your reimbursement in this transformed market landcape. Discover how Loon's AI-powered platform can help you balance clinical and economic evidence for successful market access.

Developing comprehensive cost-effectiveness analyses demonstrating long-term value
Implementing innovative payment models including outcomes-based agreements
Generating real-world evidence to support economic arguments
Engaging payers early to understand and address their concerns
Early economic planning is essential for market success
Payer engagement should begin during clinical development
Innovative pricing models can overcome initial resistance
Real-world evidence generation supports value arguments
Establish integrated evidence planning team by Phase II
Conduct comprehensive payer landscape analysis
Develop initial health economic models early
Schedule scientific advice meetings with key HTA bodies
Align clinical endpoints with payer value drivers
Plan for real-world evidence generation
Audit current development programs for economic evidence gaps
Establish integrated evidence planning teams for all Phase II+ programs
Invest in AI-powered tools for evidence synthesis and market access planning
Initiate early dialogues with key payers and HTA bodies
Develop flexible value propositions that can adapt to evolving payer priorities
Create feedback loops between market access outcomes and R&D planning

Hidden Risks in Biopharma: Clinical and Economic Evidence

The New Reality of Drug Development

The Dual Mandate: Clinical and Economic Evidence

Learning from Real-World Examples

Strategies for Success

Leveraging Technology for Evidence Excellence

Building a Balanced Evidence Strategy

Frequently asked questions

What is economic evidence in the context of pharmaceutical development?+

When should companies start developing economic evidence?+

What is the difference between regulatory approval and HTA?+

What are common mistakes in balancing clinical and economic evidence?+

How can Loon Waters™ help balance clinical and economic evidence?+

What makes a strong cost-effectiveness model?+

When and how should companies engage with payers?+

What role does real-world evidence play in demonstrating value?+

Why is budget impact analysis crucial for market access?+

What future trends will impact evidence requirements?+